Biotech News

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

Corcept (CORT)Corcept2026-06-25 13:46 ESTCommercial

REDWOOD CITY, Calif. --(BUSINESS WIRE)--Jun. 17, 2026-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the

Open original release

Related news

CORTCorcept2026-06-25 13:46 EST

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

CORTCorcept2026-06-25 13:46 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-06-25 13:46 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-25 13:46 EST

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

CORTCorcept2026-06-25 13:46 EST

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

CORTCorcept2026-06-25 13:46 EST

(Español) FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-06-25 13:46 EST

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-06-25 13:46 EST

Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session

CORTCorcept2026-06-25 13:46 EST

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

CORTCorcept2026-06-25 13:46 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

View all latest news

Corcept

Corcept is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

CORTCorcept2026-06-26 10:42 EST

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-26 10:42 EST

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

CORTCorcept2026-06-26 10:42 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

CORTCorcept2026-06-26 10:42 EST

Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-26 10:42 EST

Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States